Novartis, Pfizer seek U.S. approval of meningitis vaccines

Tue Jun 17, 2014 10:48am EDT

The entrance of Pfizer World headquaters in New York City, August 31, 2003.  REUTERS/Jeff Christensen

The entrance of Pfizer World headquaters in New York City, August 31, 2003.

Credit: Reuters/Jeff Christensen

Related Topics

(Reuters) - Pfizer Inc and rival Swiss drugmaker Novartis AG on Tuesday said they had asked U.S. regulators to approve their vaccines to prevent meningitis infections in people aged 10 to 25.

The companies are pushing for FDA approval of their respective vaccines following recent widely publicized outbreaks of the dangerous infectious disease at Princeton University and at the University of California at Santa Barbara (UCSB).

Vaccines from both companies, which have been in development for years, are designed to protect against the B strain of the meningococcal bacterium, which causes about 40 percent of U.S. meningitis infections each year and which current vaccines do not protect against. Different vaccines are already available to protect against other strains of the bacterium.

Novartis' new product against the B strain, called Bexsero, has been approved in 34 countries, including the European Union and Canada, since last year. And under a special designation from the FDA, Novartis provided nearly 30,000 doses of Bexsero to students and staff at Princeton and to UCSB in order to help control their outbreaks.

Pfizer's experimental product, named rLP2086, is being evaluated in more than 20,000 participants. Analysts are expecting it to generate annual sales of more than $500 million by 2020, if it is approved.

Both vaccines have been granted "breakthrough therapy" designations from the U.S. Food and Drug Administration, meaning they are deemed likely to show big improvement over existing products and deserve more intensive FDA feedback on how to efficiently develop them.

Meningitis is spread through coughing and exchanges of saliva, and people living in dormitories or other crowded living quarters are especially at risk.

Bacterial meningitis can cause the membranes covering the brain and spinal cord to swell. The most severe cases can result in death, hearing loss, brain damage, kidney disease or require the amputation of limbs. Symptoms include fever, headaches and stiff neck.

(Reporting by Ransdell Pierson; Editing by Marguerita Choy)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (3)
PICUDOC wrote:
Vaccine against Type B would be great.
Last paragraph confuses meningococcal meningitis with meningococcemia, sepsis from the same organism. patients with meningitis alone have a generally much better outlook than tose with sepsis and no meningitis. Media usually refers to the worst cases (sepsis) asl “meningitis” but that isnot strictly accurate.

Jun 17, 2014 2:40pm EDT  --  Report as abuse
VaccineRisks wrote:
I feel uncomfortable about Bexsero.
I asked the Director of Immunisation, UK dept of health two questions:
1. Regarding OMVs (outer membrane vesicles), I understand that they are involved in creation of antibodies. Do they also function as adjuvant?
2. What is the function of histidine?

Answer received:
1. It is not possible to answer if they have an adjuvanting effect – that certainly was not the reason for the inclusion of the OMVs.

2. I suggest you contact Novartis for information on the histidine content.

Jun 17, 2014 3:43pm EDT  --  Report as abuse
VaccineRisks wrote:
I asked the Director of Immunisation, UK dept of health two questions:
1. Regarding OMVs (outer membrane vesicles), I understand that they are involved in creation of antibodies. Do they also function as adjuvant?
2. What is the function of histidine?

Answer received:
1. It is not possible to answer if they have an adjuvanting effect – that certainly was not the reason for the inclusion of the OMVs.

2. I suggest you contact Novartis for information on the histidine content.

Jun 17, 2014 3:43pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.